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1. Introduction
1.1. Early- vs. Late-Stage Modification of Multi-Functional
Compounds
C@H functionalisation is fundamental in synthetic chemis-
try, yet it can be thought of as one of the most challenging
reactions. For a long time, the modification of non-activated
carbons in alkanes or arenes is indispensable in providing
carbon feedstocks required for synthesis.[1] For example,
radical halogenation of aliphatics is a traditional means of
functionalising the C@H bond of alkanes. However, the
selective C@H modification of more complex molecules is
a supreme challenge, since orthogonality and compatibility
with existing functionalities are essential preconditions for
achieving diversification.
Targeted late-stage modification performed as one of the
final synthetic steps as part of a multistep route offers the
possibility for diversification, so that C@H and C@heteroatom
bonds can be addressed selectively in the presence of other
functional moieties (Scheme 1). Among many areas of
application, drug discovery and natural product derivatisation
profit tremendously from achievements in late-stage func-
tionalisation (LSF): Compound libraries are typically built up
and modified from easily accessible building blocks, paving
the way for success in pharmaceutical development. Despite
obvious advantages, compatibility and avoidance of cross-
reactivity are major demands that need to be addressed
during late-stage modification.
Metal catalysis is undoubtedly at the forefront of LSFs
where C@O, C@N, and C@C bond formation, as well as
halogenation are most sought after.[2] In addition organo-
catalysis, photo-, and also electrochemistry have proven
useful within this field.[3–5] In recent years, biocatalysis has
gratifyingly emerged as a new methodology for LSF. Despite
the immense number of highly functionalised molecules in
a cell, enzymes enable the synthesis of complex metabolites in
aqueous systems, without the need for protecting or directing
groups, thus making enzymes ideal catalysts for LSF.
Nowadays, both the bulk and fine chemical industries
make use of enzymes in manufacturing processes for achiev-
ing selectivity and sustainability. The importance of biocata-
lytic transformations in industry was recently reviewed in
depth by Wu et al.[6] In 2018, a retrosynthetic perspective on
how biocatalysis can work hand in hand with chemocatalysis
to facilitate synthesis was reported.[7] Tremendous research
efforts and an endless number of novel enzymes are beginning
to unlock the huge potential for late-stage modifications. This
is of increasing interest both from a drug discovery and high-
throughput experimentation perspective where the availabil-
ity of orthogonal and robust methods is highly desirable.[8]
The advent of late-stage biotransformations along with their
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Enzyme catalysis is gaining increasing importance in synthetic
chemistry. Nowadays, the growing number of biocatalysts accessible
by means of bioinformatics and enzyme engineering opens up an
immense variety of selective reactions. Biocatalysis especially provides
excellent opportunities for late-stage modification often superior to
conventional de novo synthesis. Enzymes have proven to be useful for
direct introduction of functional groups into complex scaffolds, as well
as for rapid diversification of compound libraries. Particularly
important and highly topical are enzyme-catalysed oxyfunctionalisa-
tions, halogenations, methylations, reductions, and amide bond
formations due to the high prevalence of these motifs in pharma-
ceuticals. This Review gives an overview of the strengths and limi-
tations of enzymatic late-stage modifications using native and engi-
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rising importance in synthesis has now motivated us to
compile the many and various achievements recently made in
this field. This Review presents a streamlined state-of-the-art
guide to convey a better understanding of the scope and
limitations of late-stage biocatalysis.
1.2. Creation of Biocatalyst Diversity
The viability of enzymatic processes in synthetic applica-
tions has evolved over the past decades.[9–11] As in conven-
tional synthesis, the existence of one or multiple (bio)catalysts
with optimised reaction conditions is critical in considering
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enzymes, e.g., for the modification of lead compounds.
Biocatalytic retrosynthesis is applied to target molecules to
identify plausible transformations and can be supported by
recently introduced computer-aided synthesis planning.[12]
Afterwards, enzyme discovery or design and engineering are
necessary to create a tailored biocatalytic route (Figure 1).
Nowadays, metagenome mining is useful to discover new
biocatalysts from environmental samples. Engineering allows
for the optimisation of a biocatalyst towards a desired
transformation and to meet the conditions required for
a certain process.[13] Undoubtedly, directed evolution, tar-
geted and site-saturation mutagenesis provide powerful
means to diversify and tailor proteins.[14, 15] Recently, ancestral
sequence reconstruction has emerged enabling resurrection
of artificial ancestors based on today known variants that are
often endowed with higher robustness and a broadened
substrate scope.[16, 17] Further information on generating
biocatalyst diversity is found in Supporting Section 1 (see
Supporting Information).
1.3. C@H Bond Activation: A Background Overview
In general, C@H reactivity is dictated by bond strength,
which in turn determines the selectivity of activation. Despite
tremendous research on C@H functionalisation, the correla-
tion between bond energetics and reactivity along with the
outcome of a reaction is sometimes hard to decipher.[18]
Not surprisingly, the nature of the C@H bond is deter-
mined by its surrounding environment so that electronic, as
well as steric properties predominate the ways that bonds are
addressed.[19] Table S1 summarises different bond strengths
and their impact on reactivity giving insight into how the
chemical environment impacts dissociation energy. Directed
as well as catalyst-controlled functionalisation are approaches
typically utilised for activation of C@H bonds
(Scheme 2).[20–22] In a directed approach existing functional
groups are harnessed to complex a metal ion, for example,
while in an ideal catalyst-controlled reaction merely the
(bio)catalyst discriminates between reaction centres permit-
ting site-specific modification.
2. Oxyfunctionalisation: Nature’s Manifold
Ways of Forming C@O Bonds
Oxyfunctionalisation within the LSF “toolbox” pro-
vides a broad scope consisting of different mono-, di-,
and peroxygenases able to catalyse the oxidation of non-
activated C@H bonds forming C@O bonds.[23, 24]
Although this transformation is predominantly cata-
lysed by P450s, the breadth of different biocatalysts
available for LSF also includes peroxygenases
(UPOs),[25, 26] flavin-dependent monooxygenases
(FMOs),[27, 28] iron/a-ketoglutarate-dependent hydroxy-
lases (Fe/aKGs),[29] diiron monooxygenases,[30] and
Rieske oxygenases.[31,32] Diversity of these enzymes is
emphasised in the variation of their active sites and
mechanistic differences (Figure 2). A detailed descrip-
tion of this background can be found in Supporting
Section 3 (see Supporting Information). We highlight
particularly new and noteworthy advancements of LSF
towards different types of C@O bond formation, with
particular regard to the implementation of these oxy-
functionalisation reactions in downstream modifica-
tions.
Scheme 1. Early-stage functionalisation generally relies on multiple
steps starting from a non-functionalised starting material. Biocatalytic
concepts towards late-stage modification of various scaffolds allow
site-specific transformations in presence of other functional groups.
Figure 1. State-of-the-art route towards a tailored bioprocess starting from
retrosynthesis up to biocatalytic diversification. The pyramid highlights
timely approaches combined to create biocatalyst diversity. To outcompete
a conventional synthesis enzymatic late-stage modification adopts a superior
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2.1. Hydroxylation
Natural products are an important source
of drug scaffolds due to their structural
diversity and biological activity.[33] In many
different natural products, drug substrates,
and metabolites, endogenous and engineered
P450s are prevalent catalysts for in vivo late-
stage C@H oxyfunctionalisation.[34–37]
Hydroxylation often has an essential role
for the further modification of natural prod-
ucts, where late-stage diversification of bioac-
tive compounds is a highly efficient approach
for exploring bioactivity and structure–activ-
ity relationships (SAR). This has been exem-
plified for the sesquiterpene class of natural
products. In vivo LSF of cyperenoic acid (1),
an anti-angiogenic drug, was feasible using the
fungus Cunninghamella elegans AS 3.2028 that produced
different isomers (Figure 3): C7S-, C8S-, C9R-, C10S-, and
C11R-hydroxylated products among which the C7S- and
C9R-hydroxy isomers display favourable cytotoxic activity
towards two tumour cell lines (HepG2 and MCF-7).[38] This
highlights the relevance of LSF to modulate biological
function by introducing a crucial modification. Instead of
using an in vivo approach, widely used P450-BM3 was later
rationally engineered to hydroxylate 1, yielding efficient
enzyme variants for bioactive C7- and C9R-hydroxylation
with excellent selectivity, highlighting the malleability of the
P450 for the diversification of a complex sesquiterpene
scaffold.[39]
Engineering of an initially unselective P450-BM3 variant
expanded on a series of different late-stage hydroxylation
products of the antimalarial sesquiterpene lactone, artemisi-
nin (2). Three variants displayed a high degree of turnover
towards the regio- and stereoselective hydroxylation of three
C(sp3)@H sites providing a chemoenzymatic platform towards
novel antimalarial agents.[40] Similarly, late-stage diversifica-
tion of the anticancer sesquiterpene lactone parthenolide (3)
was accomplished from the engineering of the same P450-
BM3 variant, to oxidise two C(sp3)@H sites (C9 and C14) and
the C1,C10-double bond.[41] Three enzymes were evolved to
catalyse the epoxidation and hydroxylation of 3, providing
important scaffolds for the synthesis of further bioactive
derivatives.[41] Furthermore, in the total synthesis of the
norditerpenoid alkaloid nigelladine A (6), an engineered
Scheme 2. Approaches towards hydrocarbon functionalisation. a) Directed and b) cata-
lyst-controlled activation are the common methods applied today to address C@H bonds.
In (b.) a regioselective hydroxylation is exemplified where a catalyst discriminates
between C@H sites.
Figure 2. Reactive species facilitating enzymatic oxyfunctionalisation
shown for diverse different oxygenase classes. a) P450 monooxyge-
nases and peroxygenases: haem-thiolate active site showing the active
“Compound I” species. b) Flavin-dependent monooxygenases: flavin
hydroperoxide. c) Fe/aKG-dependent hydroxylases: ferryl-oxo non-
haem species triggering a radical abstraction from the substrate.
d) Diiron monooxygenases: A diiron non-haem complex of the active
site functions as the reactive bridging oxo-species. e) Rieske oxygen-
ases: non-haem iron centre (red) bridging to the [2Fe–2S] cluster
(blue); adopted from Barry et al.[31]
Figure 3. Regio- and stereoselective hydroxylation of the sesquiterpene
scaffolds. Hydroxylation sites are shown in red.
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P450-BM3 variant was able to catalyse a regioselective allylic
oxidation at C7, enabling a subsequent Dess–Martin oxida-
tion to the desired target molecule (Scheme 3). This under-
scores the advantage of biocatalysis since the use of an array
of traditional chemical oxidants resulted in poor selectivity
and over-oxidation.[42]
Chemoenzymatic synthesis has also been demonstrated in
a one-pot, two-step cascade, where the first step was
a palladium-free Sonogashira cross-coupling to a benzofuran
(9), followed by hydroxylation using a BM3 variant facilitat-
ing the loss of formaldehyde and affording the bis-2-
substituted product (11).[43] Furthermore, the chemoenzy-
matic regio- and stereochemical diversification of the macro-
cyclic skeleton of pikromycin (12 a/b) was initiated via
a combination of click chemistry and esterification prior to
hydroxylation catalysed by the engineered P450 PikC
(Figure 4).[44] This study emphasised how a P450 triple
mutant derived from a biosynthetic pathway could be evolved
into a synthetically viable biocatalyst permitting late-stage
diversification of cyclic motifs.
The regio- and stereoselective late-stage hydroxylation of
steroids proves challenging and often requires multi-step
syntheses, yet selectively decorating the steroid scaffold is
essential for drug synthesis.[45] P450s have the capability to
overcome this problem: Recently, different wild-type fungal
P450s (STH10, CYP5150AP2, CYP5150AP3, and
CYP5150AN1) were shown to have distinct regioselectivities
towards the hydroxylation of 11-deoxycortisol (13), yielding
19-, 11b-, 7b-, 6b-, and 2b-hydroxy-11-deoxycortisol
(Figure 5).[46, 47] The access to the 19-hydroxylation is pivotal
to the chemoenzymatic production of 19-norsteroidal phar-
maceuticals whilst steroidal 7b-alcohols exhibit anti-inflam-
matory and neuroprotective properties.[46,48, 49]
Thus very recently, P450-BM3 was engineered to effi-
ciently catalyse the LSF of six different steroids with high
regio- and stereoselectivity (14 ; adrenosterone; nandrolone;
epistosterone; androstenedione; d-ethylgonenedione) yield-
ing their respective 7b-alcohols whilst the C16 position with
distinctive a- and b-diastereoselectivity succeeded by directed
evolution as exemplified for another set of steroids.[50, 51]
Furthermore, a P450-BM3 mutant was used to selectively
synthesise the steroid 1b-hydroxydeoxycholic acid (15) and its
deuterated analogue on a milligram scale.[52] Notably, the
screening of P450-BM3 libraries has been shown to be
a lucrative endeavour for LSF, with variants oxidising an
array of human drugs: chlorzoxazone, testosterone (14),
amitriptyline, lidocaine, diclofenac, naproxen, and noscapine,
thus emphasising the impact of P450 hydroxylations on the
synthesis of putative human drug metabolites.[53,54]
Development of P450s for the production of valuable
oxygenated terpene intermediates for further functionalisa-
tion also provides a gateway to high value carotenoids and
vitamins.[55] For example the engineering of P450cam and
P450-BM3 facilitated a shift in the selective hydroxylation of
the monoterpenes 1,4- (16) and 1,8-cineole (17) inducing two
stereocentres (Figure 6).[56]
Multi-oxyfunctionalisation provides an additional
approach exploited in biocatalysis. A wild-type P450, TxtC,
is capable of both aliphatic and aromatic C@H hydroxylation
Scheme 3. Chemoenzymatic synthesis using engineered P450-BM3
variants: a) Hydroxylation enables subsequent Dess–Martin oxidation
to norditerpenoid alkaloid nigelladine A (6); b) alternatively, Sonoga-
shira reaction precedes P450 hydroxylation affording the bis-2-substi-
tuted benzofuran derivative (11).
Figure 4. Regioselective hydroxylation of pikromycin motifs 12 a and
12b. Diversity sites are highlighted by a red circle.
Figure 5. Regio- and stereoselective hydroxylation of different steroids.
Diversity sites highlighted in the red circle.
Angewandte
ChemieReviews
16829Angew. Chem. Int. Ed. 2021, 60, 16824 – 16855 T 2021 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH www.angewandte.org
in the LSF of a diketopiperazine (18).[57, 58] Moreover, recent
examples report on the dihydroxylation of either two
aliphatic or aromatic C@H bonds within a vitamin D2 motif
and benzene derivatives, respectively.[59, 60] Wild-type
CYP109E1 has been identified to highly regio- and stereose-
lectively hydroxylate vitamin D2 via two-step dihydroxyla-
tion (Figure 7).[59]
Additionally, P450s have been engineered towards multi-
ple oxyfunctionalisations.[60,61] A triple mutant of CYP154E1
was able to catalyse the consecutive oxidative N-demethyla-
tion and regio-and stereoselective C6-hydroxylation to afford
the antidepressant (2S,6S)-hydroxynorketamine (20) from
(S)-ketamine.[61] Furthermore, the use of multiple enzymes
for different oxyfunctionalisations has been shown for the
anti-cancer kinase inhibitor, vandetanib, which was oxidised
to N-desmethylvandetanib (21) and vandetanib N-oxide (22)
via P450 and FMO, respectively.[62]
LSF hydroxylation reactions catalysed via non-haem
oxygenases from biosynthetic pathways were shown for
FMOs, Rieske oxygenases, diiron oxygenases, and Fe/aKG-
dependent ones. FMO-catalysed chemoenzymatic synthesis
yielded a diverse array of stereodivergent azaphilone natural
products.[63] Within the biosynthesis of the polyaromatic
pyranonaphthoquinone antibiotic actinorhodin (23), two
consecutive hydroxylations take place at the C6 and C8
positions via a two-component FMO (Figure 8).[64] Sequential
dihydroxylation within the natural product pathway of
saxitoxin has recently been shown to be catalysed by two
Rieske oxygenases. Each enzyme was responsible for a regio-
and stereoselective hydroxylation from b-saxitoxinol to yield
11-b-hydroxysaxitoxin (24).[65] Furthermore in the biosynthe-
ses of platensimycin (25) and platencin (26), a non-haem
diiron monooxygenase hydroxylates at the C5 b-position
facilitating facile diversification of these natural products.[66]
The breadth of different oxygenases and compound classes
available for hydroxylation highlights the essential role of this
late-stage oxyfunctionalisation in Nature.
2.2. Epoxidation
Late-stage oxyfunctionalisation of carbon@carbon double
bonds into epoxides affords an important motif in many
natural products, yet chemoselectivity of epoxidation over an
alternative hydroxylation site can be challenging. Notably,
late-stage selective epoxidation of the terpenoid b-cembre-
nediol (27) exhibited regio-, chemo-, and stereoselectivity
Figure 7. Multi-oxyfunctionalisation LSF. The aromatic and aliphatic
P450 TxtC-catalysed hydroxylation gives diketopiperazine derivative 18,
whilst dihydroxylation of vitamin D2 catalysed by CYP109E1 gives 19.
The consecutive oxidative N-demethylation and C6-hydroxylation of
(S)-ketamine towards 20 is catalysed by CYP154E1. Vandetanib oxida-
tion: A P450 catalyses demethylation via oxidation affording N-
desmethylvandetanib (21) and an FMO-catalysed oxidation yields
vandetanib N-oxide (22).
Figure 8. Non-haem oxygenase-catalysed hydroxylations within biosyn-
thetic natural product pathways: FMO was shown to catalyse two
hydroxylations in the pyranonaphthoquinone antibiotic actinorhodin
(23) biosynthesis prior to dimerisation. Two Rieske oxygenases intro-
duce the LSF of b-saxitoxinol to 11-b-hydroxysaxitoxin (24). A non-
haem diiron monooxygenase hydroxylates platensimycin (25) and
platencin (26) before further oxidation.
Figure 6. Regioselective hydroxylation of achiral terpenes: 1,4-cineole
(16) and 1,8-cineole (17). Diversity sites highlighted by the red circle.
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using P450-BM3 variants (Scheme 4).[67] Within this 14-
membered macrocycle, three potential epoxidation sites are
present, so that control of regioselectivity can pose a chal-
lenge.[67] P450-BM3 V78A/F87A was a parent variant later
employed in a rational engineering approach using binding
density surface maps to identify residues that could (de-
)stabilise different binding modes, favouring C7,C8-epoxida-
tion over alternative hydroxylation sites and vice versa.[68]
Systematic substrate engineering using different 14-mem-
bered cembranoids resulted in a better understanding of
regioselective oxidation by P450-BM3. The survey revealed
that the impact of ring rigidity along with directing groups can
strongly impact regioselectivity. In addition, active-site engi-
neering proved successful for tuning regioselective cembra-
noid oxidation.[69]
By combining engineering and in vivo synthesis, the late-
stage C12,C13-epoxidation into the tylactone-related anti-
biotic macrolides juvenimicin (29), rosamicin (30), and M-
4365 (31) became feasible by introducing an artificial
chimeric construct consisting of JuvD and reductase P450-
RhF into the biosynthetic pathways (Figure 9).[70]
In addition to P450s, UPOs and FMOs are important
biocatalysts for epoxidation reactions. Recently, a UPO
(CglUPO) has been identified which catalyses the formation
of the 4,5b-epoxide (32) from 14 (Scheme 5).[71]
CglUPO displayed high chemo- and stereoselectivity and
favoured the epoxidation reaction over 16a-hydroxylation.
UPOs provide a suitable alternative to more established
P450s; however low tolerance of the co-substrate H2O2 is
a notable bottleneck, making elaborate in situ regeneration
systems necessary. In contrast to P450s, UPOs are underex-
plored in LSF of complex molecules.
2.3. Spirocyclisation
The spiro motif is attractive in drug discovery due to its
rigidified conformation which can be of importance to favour
ligand–receptor interactions.[72] The prominence of spirocyclic
compounds within natural product pathways was highlighted
by Tang et al. in a review published in 2017.[24] Noteworthy,
biocatalytic spirocyclisation is currently limited to a few
extraordinary examples originating from natural product
biosyntheses as discussed below. Late-stage dihydroxylation
of cholesterol to the 5,6-furoketal of cholesterol was catalysed
via two P450s (PpCYP90G4 and TfCYP90B50), allowing
further oxidative cyclisation that produces the spiroketal
diosgenin (33, Figure 10a).[73]
Moreover, the anticancer agents (+)/(@)-notoamide A/B
(34–37) contain a spiro-oxindole moiety, introduced biocat-
alytically using two fungal FMOs (NotI and NotI’) via
sequential stereoselective epoxidation and semi-Pinacol rear-
rangement (Figure 10 b).[74] Two Fe/aKGs (SptF and SptN)
have recently been identified within the gene cluster of the
fungal meroterpenoid emeridone F from Aspergillus sp.
TJ23.[75] These two dioxygenases displayed different oxy-
Figure 9. Epoxidation of tylactone-based antibiotic macrolides: juveni-
micin (29), rosamicin (30), and M-4365 (31) catalysed via a P450
(JuvD).
Scheme 5. Stereoselective UPO epoxidation of the steroid testosterone
(14).
Figure 10. Spiroketal natural products, diosgensin (33) and notoamide
derivatives (34–37), where spirocyclisation was afforded by oxyfunc-
tionalisation catalysed by P450s and FMOs, respectively.
Scheme 4. Regio- and stereoselective epoxidation of the 14-membered
macrocyclic b-cembrenediol (27) to 7,8-epoxy-b-cembrenediol (28).
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functionalisations, where SptF catalyses an oxidative rear-
rangement preceding an epoxidation, while SptN catalyses
regio- and stereoselective hydroxylation at the C9 position
within the core motif of emeridone F (39, Scheme 6).
Presumably these enzymes are part of the biosynthetic
pathway of a spirocyclic emeridone analogue, spiroaspertrio-
ne A (40).[75] Interestingly, SptF and SptN displayed in vitro
activity towards different emeridone derivatives, demonstrat-
ing the first potential use in LSF.[75]
2.4. Deoxyfluorination
Oxyfunctionalisation can also facilitate the incorporation
of fluorine as a late-stage modification via deoxyfluorination.
The direct incorporation of fluorine as part of a biohalogena-
tion reaction is discussed in more detail in Section 3.4.
Notably, the biocatalytic regio- and stereoselective hy-
droxylation of drug moieties can be further modified by
a chemical fluorination step that was comprehensively
exemplified by Rentmeister et al.[76] For the selective two-
step chemo-enzymatic fluorination of small organic mole-
cules, an engineered P450-BM3 perfoms a highly regioselec-
tive hydroxylation. Cyclopentenones (41–43) were hydroxy-
lated at 2–3 different sites (Figure 11). Upon purification of
the hydroxylated products, deoxyfluorination was carried out
using diethylaminosulfur trifluoride (DAST, Scheme 7a).
Moreover, it was shown that the late-stage transformation
could convert a methoxy group into a fluorine substituent.
Deoxyfluorination was preceded by hydroxylation and
decomposition of the intermediary hemiacetal into the
hydroxylated intermediate (Scheme 7b).
Additionally, deoxyfluorination of larger terpenoid moi-
eties has been shown via the chemoenzymatic synthesis of the
sesquiterpene lactone derivatives (7R)-fluoroartemether (52)
and (7R)-fluoroartersunate (53).[40] The aforementioned engi-
neered P450-BM3 variant was used to accomplish regio- and
stereoselective hydroxylation of artemisinin (2), followed by
deoxyfluorination (Scheme 8). The application of biocatalyt-
ically driven deoxyfluorination expands the potential of
oxidative enzymes in the late-stage synthesis of fluorinated
drug derivatives. P450s achieve the stereoselective hetero-
functionalisation of complex molecular scaffolds, thus pro-
viding a useful alternative to much rarer fluorinases (Sec-
tion 3.4).
Scheme 6. Fe/aKG-catalysed hydroxylation and epoxidation reactions
within the biosynthetic pathway of emeridone F (39) from andiconin
(38) and their predicted involvement within the pathway of the spiro-
meroterpenoids, spiroaspertrione (40).
Figure 11. Regioselective chemoenzymatic fluorination of cyclopente-
none derivatives 41–43, catalysed via the initial P450-BM3 variants
hydroxylation preceding deoxyfluorination. Diversification sites high-
lighted in the red circle.
Scheme 7. Regioselective chemoenzymatic transformation of a methoxy
group into a fluorine substituent of a) 5-phenyloxazoline derivative 44
and b) Corey lactone derivatives (47).
Scheme 8. Chemoenzymatic deoxyfluorination of artemisinin (2)
enabling the further chemical reduction to (7R)-fluoroartemether (52)
as well as (7R)-fluoroartesunate (53).
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2.5. Non-Native Oxyfunctionalisation
Non-native oxyfunctionalisation is an emerging field that
facilitates the exploitation of engineered biocatalysts towards
non-natural reactions: Carbene transfer,[77–83] C@H amina-
tion,[84–87] S@N sulfimidation,[88] Si@H hydroxylation,[89] and
aziridination provide topical examples.[90] These novel func-
tionalisations have been accentuated in reviews on applica-
tions and engineering that are dominated by P450s.[91–93]
Common in many of these non-natural activities is the
mutation of the conserved proximal Cys to a Ser residue
within P450-BM3, which raised the reduction potential of the
ferric state; these novel enzymes were named P411s due to
the change of characteristic spectroscopic properties.[78]
Recently, enantioselective cyclopropenation of internal
alkynes was shown. An evolved P411 variant was able to
catalyse cyclopropenation of a diverse array of alkyne
substrates (54). A high degree of stereoselectivity
(> 99.9% ee) of the resultant cyclopropene (56) was achieved
by making use of the highly efficient P411 variant (TTN
, 5760, Scheme 9 a).[83] P411 variants were also capable of
chemoselective propargylic C@H insertion (58), cyclopropa-
nation (59), or [3+2]-cycloaddition (60, Scheme 9b).[83]
Enzyme variants have recently been developed towards the
stereoselective lactone carbene insertion (Scheme 10). Intro-
ducing this functionality gave rise to several analogues of
sesquiterpene–lactone amine derivatives (61–74) with high
enantio- and diastereoselectivities.[82]
Furthermore, the recent engineering of P411 towards
C(sp3)@H primary amines by highly regio- and chemoselec-
tive primary amination at allylic and various benzylic
positions has been reported (75–78, Figure 12 a–d).[87] Thus,
P411 variants have opened up a variety of new-to-nature
reactions in LSF. Complementary activities, selectivities, and
efficiencies emphasise their potential towards novel
approaches of functionalisation. Interestingly, the promiscu-
ity of P450-BM3 towards non-native activity has recently
been demonstrated by engineering the hydroxylation of
silanes to silanols (79–80, Figure 12 e).[89] Although there are
no FDA-approved silicon-containing drugs,[94] incorporation
of silicon within drug scaffolds as a bioisostere of carbon is of
increasing interest.[95, 96]
In spite of tremendous progress and a widely expanded
reaction set, novel reactions in LSF have not yet found their
way into drug discovery as robustness and a wide application
scope still must be proven.
3. Biohalogenation: Diverse Strategies of Selective
Carbon@Halogen Bond Formation
3.1. How do Halogenases Utilise
Halide Salts?
Halogenation is one of the most
prevalent organic reactions widely
applied in syntheses of bulk and
fine chemicals. Halogen atoms
often have a beneficial effect on
the potency and pharmacokinetic
properties of drug molecules as
well as being useful handles for
numerous diversifications such as
cross-couplings.[97, 98] Indeed around
30% of drugs launched during the
period from 1914–2014 harboured
a halogen atom.[97]
Halogenases simply utilise
halide ions and molecular oxygen
or hydrogen peroxide as substrates.
They are subdivided into four dif-
Scheme 9. a) Enzymatic carbene transfer catalysed by a P411 variant for the cyclopropenation of
internal alkynes. b) Chemoselective P411 variants are capable of either propargylic C@H insertion
(58), cyclopropenation (59), or [3+2] cycloaddition (60).
Scheme 10. Diversity scope of a lactone–carbene insertion panel into
a-amino primary and secondary C@H bonds using engineered variants
derived from the parent P411-C10 that was previously applied in the
aforementioned cyclopropenation (Scheme 9).
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ferent groups: (i) haloperoxidases (haem or vanadium-con-
taining enzymes); (ii) flavin-dependent halogenases (Fl-
Hals); (iii) non-haem iron/a-ketoglutarate-dependent halo-
genases (Fe/aKG-Hals);[99,100] and (iv) nucleophilic halogen-
ases (fluorinases).[101, 102] Oxidative halogenases either form
a formal “X+” species (X = Cl, Br, I) or a halogen radical
whilst fluorinases transfer a nucleophilic fluoride ion
(Scheme 11). To obtain an overview of the advancements in
halogenating enzymes, Minges and Sewald published a recent
update on state-of-the-art applications of halogenases.[103] In
addition, more details on biocatalytic halogenation are
summarised in Supporting Section 4 (see Supporting Infor-
mation).
Since haloperoxidases do not adopt a significant role in
LSF due to their inherent lack of selectivity, further discussion
is omitted herein.[104]
3.2. Flavin-Dependent Halogenases
Excellent regioselectivity and ambient reaction conditions
are outstanding characteristics of Fl-Hals.[105, 106] However, not
all Fl-Hals are synthetically useful since certain members
require a carrier-tethered substrate rather than a free-stand-
ing compound.[107,108] Today, tryptophan halogenases acting on
free tryprophan as the substrate are the best studied members.
The modular toolkit of regiocomplementary tryptophan
halogenases has been steadily expanded over the years to
selectively address the C5, C6, or C7 position of the indole
moiety of l-tryptophan (81) to give halotryptophan (82) in
the presence of O2, a halide salt and FADH2
(Scheme 12).[109–114] FADH2 must be provided in situ
through an auxiliary reaction, e.g., by a flavin reductase,
due to the inherent oxidation sensitivity of FADH2. Light-
driven reduction and nicotinamide mimics have also
proven useful alternatives to ensure FADH2 supply.
[115,116]
A bifunctional fusion protein consisting of halogenase and
flavin reductase has been created that could foster rapid
FADH2 exchange between the catalytic entities during
catalysis.[117] However, the resultant constructs exhibited
impaired product yields when compared to reactions
containing the two separate enzymes.
Crystal structures of different complementary enzymes
suggest tight binding of the substrate in the active site as
a well-suited example of catalyst control, so that the C@H
positions of the indole moiety are shielded by bulky
residues of the protein scaffold, allowing only one carbon
to be addressed by electrophilic substitution
(Figure 13).[105,118, 119]
Tryptophan halogenases accept a range of electron-
rich arenes and substituted tryptophans.[120, 121] Further-
more, LewisQ group undertook extensive investigations on
the substrate scope of various halogenases revealing
a considerably wider substrate scope than originally
assumed.[122]
Frese and Sewald brought the preparative application
of Fl-Hals forward by co-immobilising the halogenase
RebH with necessary auxiliary enzymes as crosslinked
enzyme aggregates.[123] To facilitate enzyme engineering,
a fluorescence screening based on Suzuki–Miyaura cross-
coupling as reporter reaction allowed the detection of
bromotryptophan via biaryl formation which serves as
Scheme 11. Reactive species facilitating enzymatic halogenation shown for
different halogenase classes. a) Haloperoxidases: HOCl is released from
the active site. b) Fe/aKG-dependent halogenases: Non-haem-ferryl-oxo
species triggers radical abstraction from the substrate. c) Fl-Hals: Hypo-
halous acid diffuses through a tunnel to encounter the substrate. d) Fluo-
rinases: In a SN2 reaction, fluoride is transferred onto S-adenosyl-l-methio-
nine.
Figure 12. a–d) Primary amination of allylic and benzylic C@H bonds,
biocatalysed via P411 variants. e) Examples of selective silane oxida-
tion using engineered P450-BM3 emphasising the potential to make
Si-based chemistry accessible in biocatalysis.
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a directed evolution readout.[124] Minges et al. carried out
a sophisticated evolution campaign combining random and
rational engineering to study factors influencing both thermo-
stability and activity.[125] However, despite much effort
biohalogenation is still restricted by low efficiency that must
be overcome to make these enzymes more valuable tools in
LSF.
Late-stage halogenation of large biologically active het-
erocycles has been achieved by a substrate walking approach.
After several rounds of directed evolution and stepwise
substrate modifications, bulky biologically active precursors
such as alkaloids or the b-blocker carvedilol became acces-
sible to selective biohalogenation forming the corresponding
chlorinated compounds (83–88, Scheme 13).[126] Likewise, one
of the mutants (RebH 4-V) also proved useful for the
desymmetrisation of methylenedianilines (89) by selective
induction of a stereocentre remote from the halogenation site,
which is hard to achieve chemically.[127]
Recently, Ortega et al. identified an interesting trypto-
phan halogenase involved in the biosynthesis of a 23-mer
lanthipeptide: MibH catalyses late-stage halogenation of
a tryptophan residue within a freestanding late biosynthetic
peptide precursor (91, Scheme 14) affording NAI-107 (92).[128]
MibH is highly substrate specific so that even slight variations
in the peptide substrate were not accepted, thus restricting its
use in late-stage halogenation of peptides.
While the majority of LSF examples focuses on trypto-
phan halogenases, efforts have been undertaken to discover
novel halogenases using genome mining. Accordingly, anal-
ysis of sequence similarity networks allowed the discovery of
39 new halogenases.[129] This led to the discovery and closer
investigation of halide-specific halogenases such as bromi-
nases.[130, 131] Moreover, Gkotsi et al. made an outstanding
discovery by finding a viral iodinase by genome mining
(Scheme 15). Wide substrate profiling showed a preference
for iodination of a diverse substrate panel.[132] The ability to
iodinate is particularly attractive for C@H activation, as aryl
iodides provide more versatile starting materials in cross-
coupling reactions. Yet, it remains an unsolved question how
brominases or iodinases preferably accept bulkier halides and
whether the redox potential and/or steric demands are
decisive factors in controlling halide preference.
Figure 13. Active site overlay of RebH (PDB ID: 2OA1) and Thal
(PDB ID: 6H44) highlights the modular regioselectivity of halogenases
towards l-tryptophan (81). Optimal tuning of both active sites results
in a coplanar orientation of substrate indole side chains to each other
so that either the C7 (RebH) or C6 (Thal) position is oriented towards
the catalytically relevant Lys and Glu residues. Residue numbers
differing between RebH and Thal are shown where necessary. Trypto-
phan in complex with Thal (dark grey) and RebH (green) is shown as
stick models; active-site side chains of Thal (C atoms: light grey) and
RebH (C atoms: yellow) are highlighted (O atoms: red, N atoms:
blue).
Scheme 13. a) Late-stage halogenation of different indole-derived, ster-
ically demanding compounds (83–88) achieved by stepwise directed
evolution of RebH. b) Enantioselective desymmetrisation of methylene-
dianilines (89) using RebH 4-V is provoked by the nature of substitu-
ent “R” (blue asterisk: stereocentre).
Scheme 14. Schematic representation of late-stage halogenation of
a tryptophan residue within a lanthipeptide precursor catalysed by the
non-carrier dependent tryptophan 5-halogenase MibH. FADH2 is
provided by a flavin reductase by concomitantly oxidising NADH.
Scheme 12. Regioselective enzymatic halogenation of l-tryptophan
(81) with concomitant cofactor regeneration.
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3.3. Non-Haem Iron/a-Ketoglutarate-Dependent Halogenases
Fe/aKG-dependent halogenases provide attractive tools
to address less activated C(sp3)@H moieties, a feature that has
not yet been reported for Fl-Hals or haloperoxidases.[133] The
Fe/aKG-dependent halogenase SyrB2 was the first halogen-
ase of this type that was deeply characterised.[99] Despite
requiring a carrier-tethered substrate demonstrations of
in vitro activity succeeded proving halogenation of carrier-
bound l-threonine (102) or l-alloisoleucine (Scheme 16 a).
Even pseudohalogens were accepted, affording the azidation
and nitration of 102 to 104 and 105.[134]
With the discovery of a carrier-independent Fe/aKG
halogenase, interest in this enzyme class has grown. WelO5
catalyses the selective chlorination of 12-epi-Fischer indole U
(106) in a late stage of the biosynthesis.[135] This is particularly
surprising, especially with regard to the complex nature and
the many similar C(sp3)@H positions (Scheme 16b). Later,
a few more free-standing homologues were identified.[135]
AmbO5, WelO5* (or Hw-WelO15), and Wi-WelO15 facili-
tate halogenation of structurally slightly different related
Fischer indoles and hapalindoles.[136,137]
The narrow substrate scope of these enzymes is a notable
drawback that has been tackled by protein engineering.
Hayashi et al. described the first evolution campaign of a Fe/
aKG-dependent halogenase towards non-indole type alka-
loids.[138] A martinelline-derived fragment (108) served as
a model substrate for evolution that started from low
promiscuous activity of WelO5*. Structure-guided evolution
finally gave rise to variants CA2 and CB2 differing in
regioselectivity and with pronounced increases in catalytic
parameters yielding the corresponding chlorinated deriva-
tives (109). However, similarly to the wild-type enzyme,
variant CA2 indicated significant hydroxylation activity.
Gratifyingly, for the best variant, CB2, this side activity was
abolished and a pronounced improvement in halogenation
efficiency affording 109 was noted. Likewise, engineering of
Wi-WelO15 was reported by Hoebenreich et al. The evolved
enzyme variants, created after four generations of evolution,
catalysed late-stage chlorination of non-natural hapalindole
derivatives (110, 111) on a milligram scale.[139]
The recent discovery of Fe/aKG-dependent amino acid
halogenases further extends the synthetic utility of this
enzyme class. The BesD family showed activity towards
aliphatic C@H moieties of various amino acids
(Scheme 17).[140] Remarkably, regioselective halogenation of
Scheme 15. Bioinformatic halogenase screening and identification of
an iodinase as described by Gkotsi et al. A sequential workflow starting
from genome mining gave rise to an unprecedented iodinase; exem-
plary products are shown.
Scheme 16. Representative examples of reactions catalysed by Fe/
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lysine and ornithine affording 112–114, as well as of various
aliphatic amino acids, e.g., leucine, isoleucine, and norleucine,
succeeded. Moreover, further modification using downstream
enzymes expanded the repertoire towards amino acid deriv-
atives 118–121. Biohalogenation of freestanding aliphatic
amino acids has been unprecedented before and is difficult to
achieve using other methods. Just recently, the first report on
a nucleotide halogenase was published: The Fe/aKG-depen-
dent enzyme AdeV catalyses 2’-chlorination of a deoxyade-
nosine moiety alongside a couple of other nucleotide
derivatives albeit with lower efficiencies in the latter
case.[141] Undoubtedly, Fe/aKG halogenases come along
with drawbacks, such as a narrow substrate scope and the
fact that reactions reported until today have merely been
performed on analytical or low milligram scale, which impairs
their significance in biocatalysis. Even elaborate engineering
has so far been difficult in broadening the substrate profile. It
is important to conduct further improvements: In particular,
the toolset must be extended to develop these attractive
catalysts into meaningful tools for LSF.
3.4. Fluorinating Enzymes
Organofluorines represent 38% of launched halogen
containing drugs, the second most prevalent after organo-
chlorines.[97] On the contrary, fluorinated natural products are
very rare and their biosyntheses generally involve an adeno-
syl-fluoride synthase, usually named fluorinase.[142] In 2002,
the first fluorinase was discovered in the bacterium Strepto-
myces cattleya.[143] Later, homologues of this enzyme fol-
lowed, although the breadth is still narrow.[142] Typically, the
fluorinase catalyses displacement of chloride from 5’-chloro-
5’-deoxyadenosine (5’-ClDA, 122) to generate S-adenosyl-l-
methionine (AdoMet, 123). A subsequent SN2 reaction gives
the fluorinated metabolite 5’-fluoro-5’-deoxyadenosine (5’-
FDA, 124, Scheme 18) which turns out to be cumbersome and
of low efficiency. Lowe et al. circumvented this bottleneck
and further broadened the chemoenzymatic viability of
fluorination by introducing a Finkelstein reaction.[144] In this
case, 124 could be obtained from its 5’-brominated analogue
(125) directly rather than in a two-step manner.
[18F]-radiolabelling of bioactive molecules for positron
emission tomography (PET) is an area where fluorinases are
advantageous in achieving the site-selective incorporation of
[18F]-labels.[145] For instance, bulkier moieties such as the
cyclic peptide c[RGDfK] can be attached via an alkyne-
derived linker (126) so that 18F-fluorination of derivative 127
was possible (Scheme 19).[146] In a similar manner, fluorinase-
catalysed transhalogenation was utilised for antibody pretar-
geting, as well as in labelling of a pharmacophore targeting
prostate cancer tumours.[147, 148]
Despite previous approaches striving to increase fluori-
nation efficiency by substrate optimisation and reaction
engineering, the use of fluorinases in late-stage labelling
remains frustratingly rare due to low kinetic efficiencies and
a very limited substrate range.
Endeavours to increase efficiency by directed evolution
provided moderately improved fluorinase variants.[149,150] In
general, further efforts towards relaxing substrate specificity
and simplified syntheses to obtain cofactor analogues is
mandatory so that enzymatic fluorination can become
a pivotal tool in the synthesis of pharmaceuticals.
3.5. Aryl Diversification by Combination of Biohalogenation and
Cross-Coupling Reactions
The combination of biohalogenation with Pd-catalysed
cross-coupling is an excellent means for late-stage C@C bond
Scheme 17. Halogenation of freestanding amino acids using halogenases of BesD family. Representative biotransformation products and the
enzymes involved are depicted.
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formation. Bio- and chemocatalytic cascade processes are
particularly attractive, since the high specificity of enzymes is
joined with the plethora of transformations in chemocatal-
ysis:[151] Along with a preceding enzyme-catalysed halogen-
ation, Suzuki–Miyaura cross-coupling, Mizoroki-Heck and
Sonogashira reactions afforded substituted tryptophans (129–
132, Scheme 20a).[152–155] By using the aforementioned RebH
variant 4-V selective halogenation of different bioactive
arenes (e.g. 88, 135) and following cross-couplings were
carried out (Scheme 20 b), covering C@C, C@N, and C@O
bond formations.[156] Dachwitz et al. recently showed that
Pd nanoparticles have potential as a valuable catalyst for
cross-couplings. A Suzuki reaction on both bromotrypto-
phans and bromopeptides could be performed in water and
under air at mild temperatures, an important prerequisite in
chemoenzymatic cascades to overcome compatibility
issues.[157]
Different groups succeeded in combining enzymatic
halogenation and cross-coupling in a chemogenetic approach.
This allowed for the synthesis of aryl-substituted natural
products by heterologous incorporation of halogenase genes
into biosynthetic pathways to obtain non-native metabolites
(139–140, Scheme 21).[158–160]
In vivo approaches circumvent the difficulties of handling
biosynthetic enzymes to obtain complex natural product
scaffolds but a sometimes complicated gene insertion and
insufficient tolerance of the extrinsic gene by the host
organism may eventually become problematic. Isolation of
a modified natural product from the fermentation broth is
often challenging as the purification results in low isolated
yields. Thus, this approach currently lacks wide applicability,
e.g., to obtain natural product-inspired drug libraries.
4. Late-Stage Alkylation and Acylation
C@C bond formation is fundamental in synthesis for the
construction of carbon skeletons towards complex molecules.
Manifold methodologies are available in chemistry, ranging
from the aldol reaction to the wide field of organometallics
whereas those transformations are less evolved in enzyme
catalysis.[161] Nevertheless, late-stage reactions capable of
carbon transfer onto multi-functionalised scaffolds are pivotal
in drug development.
Scheme 18. Currently applied approaches to obtain 5’-FDA (124) using either a two-step transhalogenation or a Finkelstein-type reaction
developed by O’Hagan and co-authors.
Scheme 19. Biomolecules can be attached via the alkyne group whilst
fluorination remains possible, exemplified for the late-stage
[18F] labelling of a cyclic RGD peptide derivative (127). The fluorinase
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4.1. Biocatalytic Transfer of Methyl Groups and Analogues
Notable enhancements in receptor-binding affinity can be
observed by methylation of a drug lead, a phenomenon that
medicinal chemists refer to as the “magic methyl” effect.[162]
Selective installation of methyl groups in complex molecules
can be very challenging requiring multiple chemical synthetic
steps and harsh methylation reagents.[163]
In Nature, S-adenosylmethionine (SAM or AdoMet)-
dependent methyltransferases (MTases) catalyse selective
methylation of biopolymers, e.g., nucleic acids, proteins, or
secondary metabolites, which exemplifies an inherent ability
to perform targeted methylation. AdoMet-dependent MTases
are capable of transferring a methyl group from AdoMet
(123) to a variety of nucleophiles (e.g. C, O, N, S, P).[164]
Initially, the crystal structure of catechol-O-methyltransferase
(COMT) set the basis for the design of variants producing
either meta- or para-methylated catechols and providing
building blocks towards drugs such as aliskiren and meso-
pram.[165]
However, there is an ongoing demand to improve the
viability of enzymatic methylation strategies. A severe bottle-
neck is AdoMet (123) due to its inherent instability (t1/2 =
942 min at pH 8.0 and 37 8C), cumbersome synthesis, and high
cost.[166] Attractive enzyme cascades for AdoMet supply were
reported in the past: The enzyme SalL, naturally acting as
a fluorinase (cf. Section 3.5), enables transfer of l-Met onto
Scheme 20. a) Types of Pd-catalysed cross-couplings coupled with biohalogenation for diversification of tryptophan (81). b) Examples of late-
stage diversification by halogenation using a RebH variant 4-V along with Suzuki–Miyaura cross-coupling, thus harnessing the halogenase as
a handle for selective modification.
Scheme 21. A chemogenetic approach combines halogenation of tryp-
tophan (81) with natural product biosynthesis. The resultant natural
product is modified by Suzuki–Miyaura cross-coupling in the final
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5’-ClDA (122) affording 123 (Scheme 22).[167] Combined with
an MTase, an in situ supply of donor 123 permits methylation
of a substrate nucleophile (141). Alternatively, methionine
adenosyltransferases (MAT) can be utilised to generate 123
from ATP (144) and l-Met offering the advantage of coupling
AdoMet generation with an ATP recycling system and
circumventing efforts to synthesise 122.[168]
AdoMet analogues provide a notable achievement
towards late-stage derivatisation, owing to increased cofactor
lifetime and the ability to introduce other carbon building
blocks.[169] For example, a one-pot, two-step reaction afforded
NovO-catalysed C-methylation using methionine (145) and
ClDA analogues (146) that are accepted by SalL. Even non-
native ethylation was feasible highlighting the flexibility of
this broadly studied system (Scheme 23).[166, 170,171]
Recently described carboxymethylation further expands
the scope of carbon moieties amenable for scaffold decora-
tion:[172] The rare AdoMet derivative cxSAM (152) is
produced by the synthase CmoA in situ from prephenate
(150) and 123 (Scheme 24). In addition, orthogonal variants
of MTases, COMT and CNMT (coclaurine-N-methyltransfer-
ase), were engineered towards higher donor specificity to
suppress competing methylation whilst utilising the alkyl
donor 152 to facilitate orthogonal insertion of the carboxy-
methyl residue into the acceptor substrate (153).
Liao and Seebeck recently reported on a highly innovative
AdoMet recycling system that overcomes poor atom econ-
omy and the need for complex multistep reaction systems.[173]
A halide methyl transferase (HMT) accepts an alkyl iodide
(155), e.g., methyl iodide (MeI), as a sacrificial methyl donor
(Scheme 25): The authors showed that HMT catalyses the
exergonic reaction of S-adenosyl homocysteine (143) and MeI
towards 123. Application in a cascade using a transaminase
and an MTase along with HMT afforded b-methyl-a-amino
acids.[174] The new AdoMet generation approach was
expanded in two very recent studies: Evolution of HMT
succeeded so that alkyl halides other than MeI were made
accessible. This notable achievement makes alternative types
of enzymatic alkylations possible.[175] Likewise, N-methyla-
tion, -ethylation, and -propylation of pyrazoles resulted in
unprecedented regioselectivities using engineered MTAses. A
Scheme 22. Enzymatic approaches towards generation of methyl donor AdoMet (123) essential for methylation using MTases. SalL catalyses the
substitution of the 5’-chloro substituent of 122 against l-Met affording 126. Alternatively, MATs utilise ATP (144) and l-Met to yield 123.
Scheme 23. Synthesis of an array of AdoMet analogues using SalL
along with Met (145) and ClDA (146) analogues. Modification of the
nucleobase (R2) attached to the ribose moiety has been proven useful
to rise cofactor stability. Alteration of the thioether chain (R1) permits
incorporation of alkyl residues other than methyl.
Scheme 24. cxSAM (152) is generated from AdoMet (123) and pre-
phenate (150) using the synthase CmoA. Upon engineering of ortho-
gonal MTases, finally selective carboxymethylation was achieved.
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promiscuous HMT identified from a fungus permitted the use
of various haloalkanes other than methyl iodide as the
substrates, thus generating the corresponding alkylated
AdoMet derivatives for transfer onto the pyrazole scaf-
folds.[176]
An approach for diversification called “alkylrandomisa-
tion” enabled various alkylations of a rebeccamycin deriva-
tive (156). 18 S or Se-containing analogues of AdoMet were
formed in a cumulative fashion. The promiscuity of human
hMAT2 was exploited to obtain eight analogues of AdoMet,
also including selenium derivatives that were accepted by the
MTase RebM resulting in derivatives of the anti-tumour agent
(157, Scheme 26).[171]
A combination of tyrosinase and COMT permitted late-
stage methylation of unprotected peptides:[177] Directed
hydroxylation of a tyrosine residue (156) in a peptide
sequence enabled COMT-catalysed methylation of the
newly introduced hydroxy moiety in a one-pot fashion
(Scheme 27).
More recently rational engineering of fungal O-MTases to
modulate regiospecificity in the synthesis of unnatural drug-
like O-methylated benzenediol lactone polyketides has been
described.[178] A notable advantage of in vivo systems is the
continuous production of AdoMet (123). E. coli cells were
exploited as “bio-factories” for converting dopamine into (S)-
reticuline, a key intermediate in the biosynthesis of the
pharmaceutically relevant benzylisoquinoline alkaloids mor-
phine and codeine (Scheme S1, Supporting Information).[179]
This pathway combined five microbial or plant enzymes, three
of them being different N- or O-MTases. Another example is
the engineering of E. coli cells to convert p-coumaric acid into
the flavonoid 7-O-methyl aromadendrin exhibiting anti-
inflammatory and anti-cancer activity.[180]
4.2. Friedel–Crafts Alkylation and Acylation
Friedel–Crafts reactions, discovered more than a century
ago, have become useful handles in synthetic chemistry due to
the ability to form C@C bonds on arenes.[181] Very recently,
biocatalytic counterparts of these classic reactions were
described, potentially offering manifold advantages such as
regio- and stereoselectivity that often lack in traditional
Friedel–Crafts syntheses. Hence, this emerging field offers
a new alternative for aryl modification that has been rarely
explored until now.
A recent example of Friedel–Crafts acylation was
reported by KroutilQs group. A bacterial multicomponent
acyltransferase from Pseudomonas protegens (PPATase) was
able to catalyse the regioselective C-acylation of phenol
derivatives, such as the electron-rich resorcinol derivatives
(161) by using common acyl donors (e.g. 162, Sche-
me 28 a).[182] Only recently, an example of an enzyme capable
of direct enzymatic Friedel–Crafts alkylation was described.
Natively, CylK, originating from cilindrophane biosynthesis,
catalyses the formation of an aryl@alkyl linkage to afford the
complex natural product.[183] Its biocatalytic utility was
recently exemplified showing that CylK facilitates C-alkyla-
tion of resorcinols.
Based on this, coupling of different functionalised alkyl
building blocks succeeded in C2-position. As evidenced from
these examples, further investigations are necessary to extend
Scheme 25. AdoMet regeneration by utilising easily available alkyl
iodides (155) which are accepted by HMTs. An MTase enables the
straightforward biocatalytic transfer of alkyl groups by making use of
donor molecule 123 or its derivatives.
Scheme 26. Late-stage alkylation of indolocarbozole exemplified for
a rebeccamycin derivative (156). Alkylrandomisation was performed by
coupling the human hMAT2 with MTase RebM. Four pairs of S/Se
congeners were accepted, thus forming the corresponding alkyl
derivatives (157).
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these novel, yet promising transformations towards substrates
other than compound 161 towards late-stage aryl functional-
isation with greater utility (Scheme 28b).[184]
4.3. Pictet–Spengler Reaction
The Pictet–Spengler reaction (PSR) is particularly
useful for assembling heterocyclic scaffolds in drug
design to receive differently decorated bicyclic motifs
that are of interest for structure–activity relationship
(SAR) studies.[185] Condensation between an electron-
rich arylethylamine and an aldehyde or ketone is
followed by ring closure of the intermediary iminium
ion under acidic conditions. Alkaloids, tetrahydro-
isoquinolines (THQ) and b-carbolines can be
obtained stereoselectively, providing important natu-
ral products or pharmacological scaffolds.[186,187]
Norcoclaurine synthase (NCS) and strictosidine
synthase (STR) constitute well examined Pictet–
Spenglerases (PSases) with regard to biotechnological
applications (Scheme 29a).[187] (S)-Norcoclaurine
(167) is obtained from the condensation of dopamine
(166) and 4-hydroxyphenylacetaldehyde catalysed by
NCS.[188] The PSase STR catalyses the cyclisation of
tryptamine (168) with secologanin (169) giving the
1,2,3,4-tetrahydro-b-carboline (THBC) scaffold as
found in the indole alkaloid (S)-strictosidine (170,
Scheme 29b).[189]
To introduce diversity the substituent located at
C1 of the heterocycle can be varied by choosing the
desired aldehyde component.[190] Broader substrate
profiling further revealed that different substituents,
predominantly phenyl and alkyl, could be introduced with
high enantioselectivities.[191] HailesQ and WardQs groups
recently envisaged developing PSases towards bulkier
ketone substrates (171).[192] A truncated NCS (D29TfNCS)
with low promiscuous activity against 4-hydroxyphenyl ace-
tone was rationally engineered to yield 1,1’-disubstituted
THQs (173) from methylketones (Scheme 30).
Interestingly, spiro-fused derivatives (174) were obtained
by coupling dopamine with cyclohexanones. This transforma-
tion provides a particularly interesting means for scaffold
diversification. Additionally, the substrate scope could be
expanded towards a-substituted aldehydes affording THQs
Scheme 29. Enzymatic Pictet–Spengler reaction. a) Condensation of
dopamine with aldehydes yields different THQs (167). b) Stricosidine
(170) is synthesised by condensation between tryptamine (168) and
secologanin (169).
Scheme 28. a) Friedel–Crafts acylation catalysed by an acyltransferase.
Activated acyl donors were successfully transferred to resorcinols
(161). b) Friedel–Crafts alkylation became feasible using the C@C
coupling enzyme CylK.
Scheme 30. Engineering of TfNCS expanded the substrate scope towards
disubstituted, spiro- and a-methyl THQs. Representative products are shown.
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175–177 with remarkable diastereoselectivities when building
up two stereocentres.[193]
Early studies on the substrate scope and active-site
engineering of STRs indicate the enzymeQs promiscuity
towards substituted tryptamines and different aliphatic or
aromatic aldehydes albeit with lower efficiencies compared to
the native aldehyde (169).[194–196] Recently, expression opti-
misation and screening of different STRs further extended
the scope towards short-chain aldehydes. For RsSTR an
unexpected (R)-configuration of the resultant THBCs (179)
was found whilst (S)-configuration prevailed for bulkier
aldehydes (Scheme 31). Structural studies and modelling
unveiled a rationale for this peculiar selectivity switch:
Smaller aldehydes are bound in an inverted orientation,
suggesting the different stereopreference is governed by the
aldehyde.[197] This selectivity feature was exploited to synthe-
sise an (R)-harmicine precursor (182) from 178 and aldehyde
180.[198]
5. Selective Enzyme-Catalysed Amide Bond
Formation
5.1. Amide Synthesis in Nature
Amide bonds are recognised as the most prevalent motifs
found in drugs as revealed by a recent analysis of functional
groups found in medicinal chemistry papers.[199] Not surpris-
ingly, a survey in 2011 attributed 16% of all reactions applied
in medicinal chemistry to amide couplings.[200] Numerous
approaches are known and continuous development towards
selective and less toxic amidation procedures is ongoing.
Typical approaches of carboxylic acid activation require
hazardous conditions, e.g., formation of acyl chlorides, use
of carbodiimides or uronium reagents, suitable protecting
groups, as well as toxic, non-eco-friendly solvents.[201] These
shortcomings are an incentive to develop new reactions that
provide amides selectively under benign conditions.
Apart from peptide bonds as central binding motifs in
proteins, a huge number of enzymes facilitates the formation
of this important connection in natural products which gain
increasing attention in synthetic organic chemistry. In general,
hydrolases, some transferases, and ATP-dependent ligases are
in principle capable of catalysing amidations. Predominantly,
hydrolase-based approaches proceed via aminolysis often
preceded by an esterification (Scheme 32). The recently
published lipase SpL that acts on free carboxylic acids and
amines to directly afford amides in organic solvent/water
mixtures is a rare exception (Scheme S2, Support-
ing Information).[202] An overview on notable
examples on hydrolase-catalysed amidations using
lipases and penicillin G acylases is found in Sup-
porting Section 6 (see Supporting Information).
Transferases facilitate the transfer of activated acyl
donors, while ATP-dependent transformations can
directly amidate carboxylic acids under benign
conditions in water.[203] Herein, the main emphasis
is put on direct approaches facilitating amide bond
formation in the context of late-stage modifica-
tions.
In recent years, manifold enzymes part of the
ANL (acyl-CoA synthetase, non-ribosomal peptide
synthetase, luciferase) superfamily of adenylating
enzymes have been made available. These ATP-
dependent enzymes adopt a pivotal role and form
a highly diverse enzyme class: All members have in
common that ATP is utilised to facilitate activation
of the carboxylic acid (183) prior to acyl transfer. In
non-ribosomal amide synthesis, amidation pro-
ceeds via a three-step procedure: (i) adenylation; (ii) thiola-
tion; and (iii) condensation (Scheme 33).[204] ATP-grasp
enzymes form an acylphosphate intermediate (186) as the
carboxylate attacks the g-phosphate group of ATP, while
adenylation domains (A-domains) and amide synthetases
catalyse the formation of an intermediary acyladenylate
(187). Afterwards, attack by the amine occurs directly or via
a thioester intermediate (188).[205]
Scheme 31. Condensation of tryptamine with short-chain aldehydes results in
unexpected (R)-configuration of the products whilst (S)-configuration prevails for
bulkier aldehyde substrates.
Scheme 32. Common strategies of enzymatic amide bond formation starting from a carboxylic acid (183). Hydrolase-catalysed aminolysis requires
previous esterification whilst in a direct approach, the carboxylic acid serves as a substrate that is directly converted into the amide (185).
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5.2. Direct Amide Bond Formation: Examples and Recent
Developments in Late-Stage Functionalisation
l-Amino acid ligases are predominant members of the
ATP-grasp enzyme family. They often facilitate the formation
of peptide bonds in biosynthesis. A rather promiscuous ATP-
grasp enzyme was characterised from the biosynthesis of
tabtoxin: TabS is capable of forming various dipeptides from
unprotected amino acids. 136 different amino acid combina-
tions led to the formation of the corresponding dipeptides
including non-proteinogenic amino acids.[206] Although sev-
eral other l-amino acid ligases have been characterised, their
applications remain scarce due to pronounced lower produc-
tivity compared to conventional peptide synthesis and high
substrate specificity.[207–210] A significant finding towards LSF
was the identification of the grasp enzyme PGM1 from the
biosynthetic pathway of the peptide antibiotic pheganomycin
(190). PGM1 was shown to catalyse the selective N-terminal
coupling of the biosynthetic precursor peptide (189) to
different substituted acetic acids, hence providing a poten-
tially suitable means for peptide modification
(Scheme 34).[211]
N-Acyltransferases enable the transfer of acyl groups
from activated esters onto various amines. For example,
acylation of amines in water employing vinyl esters was
demonstrated for the transferase MsAcT by Paradisi and co-
authors.[212] Just recently the reactivity of MsAcT was consid-
erably tuned by mutating the active-site serine, part of the
catalytic triad, into a cysteine residue.[213] Variant S11C
afforded synthesis of thioesters and challenging tertiary
amides with an industrially viable substrate loading (Sche-
me 35 a). Furthermore, Lovelock et al. reported on a two-
enzyme platform that combines CoA ligases and acyltrans-
ferases (Scheme 35 b).[214] A coenzyme A thioester (199) is
formed from acid 183 by a ligase and attacked by the amine
nucleophile using a N-acyltransferase in the second step.
Provided that suitable pairs of ligase and acylase can be
found, a variety of amidations are covered without making
use of previously activated acyl donors.
Adenylation domains (A-domains) are widespread in
NRPS systems providing an entity for ATP-dependent
carboxy group activation. Stand-alone A-domains from an
NRPS system responsible for the biosynthesis of streptothri-
cin antibiotics in Streptomyces sp. were shown to act as self-
sufficient biocatalysts catalysing adenylation of the b-amino
acid l-b-lysine which subsequently undergoes attack either by
a PCP (peptidyl carrier protein) domain or carrier-bound l-b-
lysine to afford an oligopeptide.[215] Also, A-domain-catalysed
amidation was shown for fatty acids towards a range of
amines, also enabling the synthesis of rare N-acyl histidines
alongside other acylated compounds.[216] Diversification of
tryptophan succeeded by using the A-domain of tyrocidine
synthetase (TycA).[217] A rather specialised substrate scope
often limits the widespread use of A-domains from NRPS
systems.
In contrast, carboxylic acid reductases (CARs) natively
catalyse the reduction of carboxylic acids (183) into the
corresponding aldehyde (201).[218, 219] Structural studies and
engineering revealed CARs to be multi-domain enzymes
consisting of a distinct A-, PCP- (peptidyl carrier protein,
Scheme 33. Activation of carboxylate group by ATP-dependent
enzymes. Two approaches to utilise ATP predominate: a) In ATP grasp
enzymes, the g-phosphate is transferred upon nucleophilic attack of
carboxylate leading to a mixed anhydride (186). b) Adenylation
domains result in an acyladenylate (187). Depending on the enzyme
the activated species is directly attacked by an amine or undergoes
intermediary thioester formation. NRPS: non-ribosomal peptide syn-
thetase.
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containing a phosphopantetheine arm) and a reduction
domain (Scheme 36 a).[220] Wood et al. showed that CARs
are capable of amidation when employing an excess of amine
rather than the co-substrate NADPH, so that the reduction
function is abolished.[221] Hence, an array of benzoic and
cinnamic amides was synthesised. In a follow-up study this
concept was further streamlined by making use of a truncated
CAR variant (CARmm-A) consisting of merely the A-
domain. The authors showed that CARmm-A performs
selective mono-acylation of diamines without the need for
protecting groups. An array of carboxylic acids with loadings
up to 10 mm was utilised in a facile one-step amidation
yielding various amides (208–216), e.g., the vasodilator
cinepazide (216, Scheme 36b).[222]
Despite their current narrow substrate scope and difficult
handling due to weak expression and solubility, amide bond
forming synthetases are receiving increased attention for late-
stage modification. Wessjohan and co-authors reported on the
homologous amide synthetases CloL, SimL, and CouL
utilised in a modular fashion to modify aminocoumarin
(217). A small library of derivatives on a milligram scale was
synthesised using this system (Scheme 37a).[223] The amide
synthetase XimA was shown to catalyse the last biosynthetic
step by coupling l-threonine to the free carboxylic acid
precursor (xiamenmycin B, 221) in xiamenmycin A biosyn-
thesis (Scheme 37 b). The authors successfully expanded the
amino acid scope by rational mutant design from l-threonine
towards 11l- and 4 d-amino acids.[224]
The synthetic utility of the synthetase McbA from
Marinactinospora thermotolerans was recently reported by
Petchey et al.[225] In the native reaction, McbA catalyses
amidation of b-carbolines (222), yet McbA is not exclusively
limited to its native substrate (Scheme 38). Broad substrate
profiling indicated that a wide range of aromatic
carboxylic acids was accepted by McbA.[226] An
almost equimolar ratio of acid to amine is a significant
advantage towards amide formation, especially on
a preparative scale. In further studies, the authors
expanded the amine scope towards different aliphatic
and cyclic moieties providing a range of interesting
building blocks for diversification. Noteworthy was the
acylation of poorly nucleophilic amines, particularly
shown for a range of anilines (233–237).[227]
Biocatalytic amide bond formation is still in its
infancy and investigations into late-stage diversifica-
tion have just begun as illustrated by the presented
examples. Currently scalability and acid/amine scope
as well as the number of available enzymes are the
major limitations to be tackled to further evolve this
method in the future.
Scheme 35. a) N-Acyltransferase MsAcT S11C accomplishes difficult
acetylations with high substrate concentration due to exchange of
active-site Ser against Cys forming a covalent thioester intermediate.
b) Combination of CoA ligase and N-acyltransferase affords a broad
amide scope.
Scheme 36. a) Carboxylic acid reductases can be used for amide bond
formation rather than reduction of a carboxylic acid. b) Solely the A-
domain is sufficient to enable amidation as shown by using a truncated
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6. Reduction of Double Bonds
6.1. C=O Reduction
Reduction of C=O double bonds into the corresponding
alcohol is an atom economical and alternative approach to
stereoselective oxyfunctionalisation. An array of different
enzyme families is able to catalyse C=O reductions including
ketoreductases (KRED), aldo-keto reductases (AKRs),
medium-chain dehydrogenases/reductases (MDR), and
short-chain dehydrogenases/reductases that have been thor-
oughly reviewed by Hollmann et al.[228] In addition to an
outstanding significance in industrial biocatalysis, C=O
reductions have also emerged in late-stage synthesis.
Recently, Gong et al. focused on an LSF approach for the
synthesis of atorvastatin, an important cholesterol-lowering
drug.[229] Synthesis of the side chain (ATS-7, 239) is an
excellent example of a KRED-catalysed biotransformation
due to its high stereoselectivity (Scheme 39). Efforts were
undertaken to engineer a KRED variant with increased
activity and thermostability by directed evolution affording
the chiral alcohol in 87 % yield,> 99.5% de on a 100 mL scale
at 40 8C.[229]
Interestingly, biocatalytic introduction of deuterium is
a notable example of late-stage labelling by C=O reduction
(Scheme 40). The presence of deuterium atoms in pharma-
ceuticals can result in improved pharmacokinetic properties
such as metabolic stability.[230] Rowbotham et al. demon-
strated an elegant approach for the asymmetric reductive
deuteration by NADH reductases using H2 as the reductant
along with 2H2O as an isotope source. Hydrogenase and
NAD+ reductase were co-immobilised on carbon particles,
Scheme 37. a) Amide coupling of aminocoumarins (217) to obtain modified acylated aminocoumarins (219). b) Xiamenmycin derivatisation by
selective coupling of amino acids to 220 using XimA wild type or a mutant.
Scheme 38. Amide bond synthetase McbA catalyses amidation of b-carbolines as the native reaction. McbA accepts various aromatic carboxylic
acids. The amine scope examined for acid 222 with R1 =acetyl indicated that diverse aliphatic and aromatic amine building blocks are accepted by
McbA.
Scheme 39. Asymmetric reduction of ATS-6 by an engineered KRED
relevant for the atorvastatin side chain synthesis.
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enabling the resultant H2-driven system to reduce NAD
+ to
[4-2H]-NADH. Coupling with a KRED facilitated deuterium
transfer onto ketone 240, thus affording a labelled alcohol
(241).[231]
6.2. Late-Stage Reductive Amination and Amine Oxidation
Biocatalysis has become a powerful tool for C=N reduc-
tion to achieve selective amine formation. Several classes of
enzymes are capable of performing these reactions, such as
imine reductase (IREDs), reductive aminases (RedAms),
transaminases, amine dehydrogenases (AmDH), and short-
chain dehydrogenases/reductases (SDRs). Herein, we focus
on recent advances of amine synthesis with regard to late-
stage modification.
Biocatalytic reductive amination for the synthesis of
pharmaceutical compounds and important chemical building
blocks has been reported.[232, 233] (R)-Rasagiline (244) is a drug
used for the treatment of ParkinsonQs disease and is a well-
suited target for RedAms. Briefly, RedAms have the ability to
catalyse the asymmetric reductive amination between
ketones or aldehydes by combining both imine formation
and subsequent reduction (Supporting Scheme S4).[232] In
contrast, IREDs require formation of the imine a priori that
undergoes subsequent reduction by the enzyme.
Synthesis of 244 either started from a prochiral ketone
precursor (242) or the racemic amine (rac-244) by making use
of different biocatalytic approaches. Aleku et al. reported on
an AspRedAm variant that was able to directly produce 244
starting from 242 and propargylamine (243) with > 97%
conversion and excellent ee (Scheme 41a).
Another AspRedAm variant with selectivity for the
oxidation of (S)-244 was utilised to exclusively yield imine
244 b, thus accumulating the desired enantiomer (R)-244 by
dynamic kinetic resolution (Scheme 41b) with > 99% ee.[234]
Likewise, Matzel et al. identified an enzyme capable of
producing 244 in one step (Scheme 41c) from the same
starting materials.[233]
Manufacture of the lysine-specific demethylase-1 inhibitor
(GSK2879552, 248) for the treatment of small cell lung cancer
and acute leukaemia provides a recent example of a relevant
late-stage amination:[235] The tert-butyl ester (1R,2S)-247
could be obtained from its late synthetic precursor aldehyde
(245, Scheme 42). Through extensive engineering preceded
by the discovery of a suitable IRED from a previously built
panel (IRED-46)[236] the resultant variant was capable of
concomitant kinetic resolution of rac-246 along with reduc-
tive amination. Notably, the engineered enzyme also met the
requirements of an industrially viable process.
Amine oxidases can catalyse the opposite reactions to
IREDs, opening an attractive tool for multiple types of
functionalisations of N-containing heterocycles. Monoamine
oxidase N (MAO-N) from Aspergillus niger has been sub-
jected to extensive rounds of directed evolution and protein
engineering resulting in a set of variants (e.g. D5, D9, D10)
which have complementary substrate preference coupled
with high activity.[237] These variants are particularly active on
cyclic five-membered ring amines and catalyse oxidation to
the corresponding imine or iminium under mild conditions
(room temperature, pH 7.5, atmospheric dioxygen), a trans-
formation that is equivalent to a-C@H activation to an amine
(Scheme 43). The resulting imines/iminiums have been used
for a wide range of transformations including: (i) addition of
nucleophiles (e.g. CN, bisulfite); (ii) oxidation to lactams
Scheme 40. Reductive deuteration of carbonyl groups by making use
of a heterogeneous biocatalytic cofactor recycling system along with
a KRED and 2H2O supplying the deuterium atoms.
Scheme 41. Biocatalytic approaches for (R)-rasagiline (244) synthesis.
Scheme 42. Biocatalytic kinetic resolution and reductive amination
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(252);[238] and (iii) building blocks for multi-component reac-
tions, for example, Ugi and Ugi–Smiles.[239] MAO-N variants
have also been used in a different context, to generate both
pyrroles and pyridines from appropriate dihydro- and tetra-
hydro-precursors.[240,241] Extensive engineering of MAO-N
proved useful in desymmetrisation of API building blocks
leading to enantiomerically pure amine precursors.[242]
The late-stage amination towards the antidiabetic drug
sitagliptin (259) represents an outstanding example achieved
by Codexis and Merck (Scheme 44).[243] Evolution of a trans-
aminase facilitated reductive amination of the corresponding
precursor ketone (258) starting from a truncated methyl
ketone substrate to shape the active site towards the more
demanding ketone which finally gave 259 with excellent
enantioselectivity on an industrial scale.
7. Emerging Areas of Late-Stage Modification
7.1. Photobiocatalysis
Photobiocatalysis is a novel concept that merges the
features of organic photo- with biocatalysis which has gained
increasing attention in the past decade. In terms of C@H
activation, light-driven reactions enable high catalytic pro-
miscuity along with neat reaction conditions and functional
group tolerance.[244] A plethora of photocatalysts, for instance,
transition metals or organic frameworks, is well known to
utilise light as their energy source whereas development of
biocatalytic counterparts is still in its infancy.[245] A compre-
hensive discussion on the backgrounds of photochemical
excitation of enzyme cofactors can be found in a recent review
by Sandoval et al.[246]
Photocatalytic reactions can be combined or linked with
enzyme-catalysed transformations to unlock new catalytic
functions. In particular, NAD(P)H-dependent enzymes are
attractive biocatalytic entities as the cofactor can be excited
by visible light. Excitation of the 1,4-dihydropyridine moiety
(260) to the strong reductant 261 causes an increase in the
reduction potential of NAD(P)H, thereby allowing for
reduction of various functional groups when irradiated with
blue light (Scheme 45a).[247]
HysterQs group was able to repurpose certain substrate-
permissive enzymes by exploiting photochemical features of
their respective cofactors. Excitation of 260 within a KRED
was exploited for the dehalogenation of achiral, substituted
lactones (262). Upon excitation of NAD(P)H, the trans-
formation of a racemic 262 into the dehalogenated enantio-
pure counterpart 264 succeeded via formation of interme-
diary radical species 263 (Scheme 45b).[247, 248]
In addition to their role in oxyfunctionalisations, P450s
have become attractive tools for photobiocatalytic reac-
Scheme 43. Multiple ways of functionalisation using MAO-N and its application in heterocycle syntheses. a) Functionalisation a- to N-atom;
b) pyrrole synthesis; c) pyridine synthesis.
Scheme 44. An engineered transaminase facilitates the late-stage ami-
nation of ketone precursor 258 towards sitagliptin (259).
Scheme 45. a) Photoexcitation of the NAD(P)H cofactor into a strong
single-electron reductant. b) Application of excited NAD(P)H to the
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tions.[249] Previous reports on light-driven P450-catalysed
reactions include the use of photosystem I (PSI) from plant
cells to hydroxylate tyrosine.[250] Tran and co-workers cova-
lently attached a RuII–diimine complex to the haem domain
of P450-BM3 variants. This hybrid enzyme approach allowed
selective hydroxylation of terminal C@H bonds of fatty acids.
In addition to reaching high turnover and reaction rates, the
photo-biocatalytic entity omits the need for reductase and
NAD(P)H cofactor that streamlines the overall bioprocess
compared to native reactions using P450s.[251]
Recently, Huang and co-workers utilised the light-driven
redox-catalytic potential of flavin mononucleotide (FMN) by
applying it to the enzyme-catalysed intermolecular alkylation
of terminal alkenes (266, Scheme 46), thus creating chiral g-
substituted carbonyl compounds (267) found in many bioac-
tive substances such as piperidones, (+)-3-oxoabolene, and
(R)-4-methoxyalkanoic acids.[252] Previously characterised
substrate-permissive wild-type “Ene” reductases (EREDs)
were used as biocatalysts so that a variety of a-halo carbonyl
compounds served as substrates. These compounds are able to
form an electron donor–acceptor complex with the reduced
FMN in the enzymeQs active site, which can be excited by
visible light to initiate the radical-based alkylation pathway.
Remarkably, excellent yields and enantioselectivities
resulted. Further examples can be found in Supporting
Section 8 (see Supporting Information).
Although the application of photobiocatalysis in the field
of LSF is still in its infancy and further progress must be made
to extend the current repertoire, the studies described herein
suggest that the ability to re-task enzymes using light
provokes non-native, highly selective transformations and
presents manifold opportunities for the selective functional-
isation of multifunctional compounds.
7.2. Glycoengineering
Sugars are frequently found attached to small molecules
in Nature[253] but are also important parts of many proteins,
such as antibodies, and have also been conjugated to
DNA.[254,255] They have significant impact on biological
activity and stability. For example, 2-O-a-d-glucopyranosyl-
l-ascorbate (268) is a bioavailable and stable derivative of
ascorbic acid of relevance in the food, beverage, pharma-
ceutical, and cosmetic industries.[256] The chemical conjuga-
tion of glycans to core structures is highly challenging and
biocatalysis has been shown to achieve one-step glycosylation
with high selectivity and no need for protection strategies.[257]
A typical example is the generation of 268 directly from
ascorbic acid using cyclodextrin glycosyltransferase
(CGTase), which can catalyse transfer of a-glucose from
starch to a range of alcohols such as ascorbate with control of
regioselectivity and retention of configuration at the anome-
ric centre (Scheme 47a).[258] Using CGTase for production of
chemicals is advantageous to using the more common
biosynthetic “Leloir” glycosyltransferases for this process
because the latter enzymes require sugar nucleotide sub-
strates which can be recycled using enzyme cascades.[259]
Recently, some elegant high-throughput screening meth-
ods have been developed for the discovery of novel glyco-
sylating activities by (meta-)genome mining from large
expressed libraries of glycosidases and glycosynthases.[260,261]
Remodelling of N-glycans in glycoproteins using biocatalysis
has attracted a lot of attention due to extensive applications
for biopharmaceuticals such as therapeutic antibodies and
antibody–drug conjugates (ADCs). Antibodies generally
carry an asparagine-linked oligosaccharide (N-glycan, Sche-
me 47 b) that is important for function. The toolbox of
biocatalysts that can either trim the N-glycan sequence
selectively (endo- and exo-glycosidases) as well as conjugate
specific sugars to termini of N-glycan chains (glycosyltrans-
ferases) is steadily increasing.[262] Biocatalysis can be used to
generate natural glycan structures whereas a number of
enzymes also displays promiscuous activity, allowing for
introduction of bioorthogonal non-natural functionalities
into glycoproteins. This is of particular interest for the
Scheme 46. Intermolecular alkylation of terminal alkenes catalysed by
EREDs. Adapted from Huang et al.[252]
Scheme 47. Examples of glycosylation reactions for late-stage function-
alisation. a) Enzymatic glycosylation of small molecules such as
ascorbic acid; b) enzymatic glycoengineering of biopharmaceuticals
and introduction of non-natural bioorthogonal groups into the glycan
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production of ADCs, but also applicable to other pro-
teins.[263–265]
8. Conclusion and Outlook
LSF is an important pillar of modern synthetic organic
chemistry where tremendous efforts are being undertaken to
develop novel methodologies that are paramount for suc-
cessful drug development. One-step transformations on
complex scaffolds facilitate diversifications vital to modulate
efficacy as well as to improve crucial physicochemical
properties, drug metabolism, and pharmacokinetics (DMPK).
Enzymes have recently made their way into late-stage
modifications that are heading in manifold future directions.
Already a broad repertoire of biocatalytic transformations
can be accessed for obtaining diversified molecular scaffolds.
However, high reaction selectivity often means significant
biocatalyst specialisation that may result in a restricted
substrate profile. Ongoing efforts will solve this downside
by (a) protein engineering of niche enzymes, and by
(b) (meta-)genome mining. In addition to a plethora of
well-established examples capable of late-stage diversifica-
tion today, many more enzyme-catalysed transformations will
grow to maturity. In light of the remarkable achievements
made in biocatalysis over the past decades, the significance of
late-stage biotransformations will undoubtedly expand over
the years to come. It can be anticipated that future enzyme
catalysis can take a pre-eminent role in the initial stages of
drug discovery, where efforts to miniaturise compound syn-
thesis and screening in a high-throughput format gain more
importance.
There is an almost infinite number of biocatalysts and
orthogonal biotransformations utilised in Nature to selec-
tively modify polyfunctional compounds. To date we have
only scratched the surface of what is possible.
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